TABLE 2.
Summary of subgroup analysis with random effects SMD (95% CI). *Statistically significant variables at p-value <0.05.
| Primary outcome | HbA1c | Dose | Duration | |||
|---|---|---|---|---|---|---|
| HbA1c<8% | HbA1c ≥ 8% | <3 g/d | ≥3 g/d | <12 weeks | ≥12 weeks | |
| Triacylglycerol | −0.16 (−0.39, 0.06) | −1.07 (−1.31, −0.83) | −0.81 (−1.03, −0.59) | −0.33 (−0.58, −0.08) | −0.42 (−0.76, −0.09) | −0.66 (−0.84, −0.47) |
| p = 0.158 | p < 0.05 | p < 0.05 | p < 0.05 | p < 0.05 | p < 0.05 | |
| HDL cholesterol | 0.21 (−0.02, 0.45) | 0.93 (0.69, 1.16) | 0.94 (0.72, 1.160) | 0.14 (−0.1.0.39) | 0.39 (0.05, 0.73) | 0.63 (0.44, 0.81) |
| p = 0.074 | p < 0.05 | p < 0.05 | p = 0.244 | p < 0.05 | p < 0.05 | |
| LDL cholesterol | −0.16 (−0.39, 0.06) | −0.97 (−1.21, −0.74) | −0.80 (−1.03, −0.58) | −0.26 (−0.5, −0.01) | −0.02 (−0.35, 0.32) | −0.73 (−0.92, −0.54) |
| p = 0.16 | p < 0.05 | p < 0.05 | p < 0.05 | p = 0.923 | p < 0.05 | |
| Total cholesterol | 0.17 (−0.06.0.39) | −0.87 (−1.15, −0.59) | −0.043 (−0.66, −0.20) | 0.00 (−0.27, 0.27) | 1.11 (0.73, 1.48) | −0.63 (−0.83, −0.43) |
| p = 0.153 | p < 0.05 | p < 0.05 | p = 0.995 | p < 0.05 | p < 0.05 | |
| HbA1c | −0.21 (−0.43, 0.01) | −0.91 (−1.09, −0.74) | −0.79 (−0.99, −0.59) | −0.48 (−0.67, −0.29) | −0.29 (−0.58, 0.00) | −0.73 (−0.88, −0.57) |
| p = 0.059 | p < 0.05 | p < 0.05 | p < 0.05 | p = 0.053 | p < 0.05 | |
| Fpg | −0.18 (−0.40, 0.04) | −0.80 (−0.98, −0.61) | −0.67 (−0.88, −0.46) | −0.44 (−0.63, −0.25) | −0.68 (−0.94, −0.41) | −0.49 (−0.66, −0.32) |
| p = 0.1 | p < 0.05 | p < 0.05 | p < 0.05 | p < 0.05 | p < 0.05 | |